White Paper
Pakistan’s Advantage in Hepatitis Delta & MASH Trials
Accelerating Global Liver Disease Research: Pakistan’s Unique Strengths in Hepatitis Delta & MASH Clinical Trials
Dec 19, 2025
Pakistan is rapidly emerging as a leading destination for Hepatitis D and Metabolic Associated Steatohepatitis (MASH) clinical trials, offering pharmaceutical and biotechnology companies access to large, treatment-naïve patient populations and a mature research ecosystem. With internationally aligned regulations, robust infrastructure, and proven operational excellence, Pakistan enables rapid recruitment, high patient retention, and reliable data delivery. Supported by IQVIA’s regional expertise and strong community engagement, the country’s collaborative environment and modernised regulatory framework make it an ideal setting for advancing global liver disease research and accelerating the development of new therapies.